DXCM: Future CGM Adoption And Trial Data Will Test Premium Expectations

DexCom's analyst fair value estimate has been revised higher to about $67.93. Analysts point to stronger expectations around continuous glucose monitor adoption, positive CONNECT data, and easing concerns following investor day updates as key drivers behind a higher assumed revenue growth rate and a premium future P/E multiple, partly offset by a lower profit margin outlook.

Analyst Commentary

Recent Street research on DexCom reflects a generally constructive view on the company and the continuous glucose monitor market, but also highlights a clear split between more optimistic and more cautious outlooks. Several firms have raised price targets after reviewing CONNECT data, broader coverage initiatives, and feedback from physicians, while others have trimmed targets or kept more conservative assumptions in place.

On the more positive side, some analysts argue that DexCom could be benefiting from easing concerns following its investor day, with expectations that continuous glucose monitor adoption and coverage expansion efforts, including in Type 2 non insulin treated populations, may support the case for a premium P/E multiple. Multiple research notes reference the CONNECT dataset as encouraging for payers and point to survey work that suggests supportive sentiment among endocrinologists and primary care physicians toward continuous glucose monitoring.

At the same time, the analyst community is not uniformly upbeat. A group of more cautious voices has pulled back price targets or adopted less aggressive assumptions after the company’s analyst day and follow up work, citing the level of growth targets, sector multiples, and execution needs against long term goals. These mixed views help frame the upside and downside arguments that investors may want to weigh when assessing DexCom’s valuation.

Bearish Takeaways

Bearish analysts have reduced price targets into the US$60s and US$80s range after the investor day, pointing to DexCom’s multi year growth targets as slightly below some prior expectations and arguing that this may limit upside for the stock valuation if execution does not outpace those goals.
Some bearish analysts highlight that sector valuation multiples have compressed, leading them to apply lower forward P/E assumptions for DexCom than in prior models, which in turn reduces their fair value estimates even if underlying business assumptions are broadly intact.
Cautious research notes flag execution risk around DexCom’s long term financial targets, including the need to deliver on product launches and expanded global coverage, suggesting that any delays or weaker than planned adoption could pressure both growth expectations and the premium multiple the stock has historically carried.
A subset of bearish analysts indicate that expectations for continuous glucose monitor adoption and revenue growth are already high, which they see as increasing the risk of disappointment if CONNECT data, reimbursement decisions, or competitive dynamics do not fully support the more optimistic scenarios embedded in market forecasts.

Overall, the current research mix on DexCom sets up a debate between those who see recent data, coverage expansion efforts, and physician feedback as support for a higher valuation multiple, and those who emphasize execution risk, more conservative sector multiples, and already elevated expectations. For investors, this split can be useful context when comparing personal assumptions with the range of Street views now embedded in price targets and fair value estimates.

What's in the News for DexCom

FDA clearance of DexCom's Stelo Glucose Biosensor System as the first over the counter continuous glucose monitor for children aged two and older who do not use insulin, expanding its existing adult indication and targeting broader pediatric metabolic and diabetes use cases. (Source: company and FDA announcement)
CONNECT randomized controlled trial results showing clinically and statistically significant improvements in glycemic control and HbA1c for adults with Type 2 diabetes not using insulin when using Dexcom G7 compared with routine care. This positions continuous glucose monitoring as a potential standard of care for this group. (Source: CONNECT trial news)
Planned relaunch of a reimagined Stelo app in the U.S. starting July 2026, with AI powered features such as pattern recognition, proactive coaching, and personalized summaries. There are also plans for international expansion of the Stelo platform into the UK, Australia, New Zealand, and South Korea from late 2026 into 2027. (Source: Stelo app and global rollout announcement)
Agreement to acquire Nutrisense, a CGM based wellness and nutrition platform, to add registered dietitians, personalized nutrition guidance, and behavior change support on top of DexCom's glucose data offering. (Source: Nutrisense acquisition announcement)
FDA enforcement reports and voluntary Class II recalls related to Dexcom G7, Dexcom ONE, and Dexcom ONE+ iOS and watchOS apps because of a software defect that can delay glucose data and alerts, with worldwide distribution affected and remediation actions ongoing. (Source: FDA enforcement and recall notices)

Valuation Changes for DexCom

Fair Value: $65.00 has moved higher to about $67.93, reflecting modestly stronger inputs in the updated model.
Discount Rate: The discount rate has fallen slightly from 7.89% to about 7.53%, which mechanically supports a higher present value for DexCom's projected cash flows.
Revenue Growth: The long term revenue growth assumption has risen slightly from about 9.79% to roughly 10.37%, signaling a somewhat stronger outlook for DexCom's top line potential.
Net Profit Margin: The profit margin assumption has been reduced from about 21.80% to roughly 18.16%, indicating a more cautious view on future profitability even as growth expectations improve.
Future P/E: The future P/E multiple has increased from around 21.6x to about 26.4x, implying a higher valuation multiple applied to DexCom's expected earnings.

1 view

Catalysts

About DexCom

DexCom develops and sells continuous glucose monitoring systems used by people with diabetes around the world.

What are the underlying business or industry changes driving this perspective?

Although broader commercial coverage for type 2 diabetes patients not using insulin, including more than 6 million covered lives across large PBMs and an expected expansion to over 7 million with Prime Therapeutics, supports a larger addressable base, future revenue growth still depends on converting the roughly two thirds of covered patients who are not yet using CGM. This may cap near term growth if adoption remains slow relative to coverage additions, with a knock on effect for earnings.
Despite DexCom’s focus on securing Medicare and other global reimbursement for type 2 non insulin users, the timing and any conditions attached to possible CMS coverage remain uncertain. As a result, the company’s long term revenue mix and margin profile could be pressured if this large population is reached more slowly than management aspires to, particularly for U.S. revenue and operating margin expansion.
While demand for longer wear sensors and accuracy improvements is reflected in the G7 15 Day launch and customer feedback, maintaining current gross margin levels could be challenging if higher resin and fuel costs persist. DexCom is already accounting for a 50 to 100 basis point potential impact from oil related inputs, which could limit further gross margin and EBITDA margin improvement.
Although AI driven features such as the redesigned Stelo app and the DexCom Smart Basal dosing module may support better user engagement and retention, integrating these tools into varied clinical workflows and consumer habits takes time. Any friction in adoption could moderate growth in active users and reduce the uplift to revenue and net margins that higher utilization typically brings.
While international markets have been a source of strong reported growth, future contribution depends on continued access wins, tender outcomes and successful launches of products like Stelo and a new CGM system. Any slower than hoped uptake or less favorable pricing in these regions could weigh on overall revenue growth and limit further operating margin leverage.

NasdaqGS:DXCM Earnings & Revenue Growth as at May 2026

Assumptions

How have these above catalysts been quantified?

This narrative explores a more pessimistic perspective on DexCom compared to the consensus, based on a Fair Value that aligns with the bearish cohort of analysts.
The bearish analysts are assuming DexCom's revenue will grow by 10.4% annually over the next 3 years.
The bearish analysts assume that profit margins will shrink from 19.3% today to 18.2% in 3 years time.
The bearish analysts expect earnings to reach $1.2 billion (and earnings per share of $2.98) by about June 2029, up from $930.4 million today. However, there is some disagreement amongst the analysts with the more bullish ones expecting earnings as high as $1.6 billion.
In order for the above numbers to justify the price target of the more bearish analyst cohort, the company would need to trade at a PE ratio of 26.4x on those 2029 earnings, down from 28.5x today. This future PE is greater than the current PE for the US Medical Equipment industry at 25.7x.
The bearish analysts expect the number of shares outstanding to decline by 1.6% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.53%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Broader commercial coverage for type 2 non insulin patients, including more than 6 million currently covered lives and an expected increase to over 7 million with Prime Therapeutics, could support higher CGM adoption over time, which would be a positive surprise for revenue and earnings.
Potential CMS coverage for type 2 non insulin users, together with upgraded ADA standards of care and growing real world evidence and randomized controlled trial data, may expand the eligible population and support a higher long term active user base, which would be supportive for revenue and net margins.
Product improvements such as the G7 15 Day sensor, new adhesive technology, AI driven Stelo app redesign and Smart Basal dosing feature, along with consistently high customer satisfaction scores, could support better retention and utilization, which would benefit revenue, gross margin and operating margin.
Continued international access wins, tender participation and new launches such as Stelo and a new CGM system, combined with the existing 26% reported international revenue growth and 17% international organic growth in Q1 2026, may sustain a higher contribution from overseas markets, which would support revenue growth and EBITDA margin.
DexCom’s strong current financial position, including Q1 2026 worldwide revenue of US$1.19b, gross margin of 63.5%, operating margin of 22.2%, adjusted EBITDA margin above 30% and a cash balance of US$2.4b with significant free cash flow, provides capacity for continued investment in R&D, manufacturing and possible acquisitions. This could support future revenue, earnings and net margins.

Valuation

How have all the factors above been brought together to estimate a fair value?

The assumed bearish price target for DexCom is $67.93, which represents up to two standard deviations below the consensus price target of $85.24. This valuation is based on what can be assumed as the expectations of DexCom's future earnings growth, profit margins and other risk factors from analysts on the more bearish end of the spectrum.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $112.0, and the most bearish reporting a price target of just $65.0.
In order for you to agree with the more bearish analyst cohort, you'd need to believe that by 2029, revenues will be $6.5 billion, earnings will come to $1.2 billion, and it would be trading on a PE ratio of 26.4x, assuming you use a discount rate of 7.5%.
Given the current share price of $68.65, the analyst price target of $67.93 is 1.1% lower. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on DexCom?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystLowTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystLowTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystLowTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Type 2 Coverage Expansion And AI Features Will Shape A Balanced Long Term Outlook